FOXP3 and breast cancer: In addition, both CD8 +TILs and a high CD8/FOXP3 ratio have been associated with pCR rates in luminal-like BC patients with a luminal-B phenotype receiving neoadjuvant treatment with anthracycline (+/−taxane) [66,67].